Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TGN-1412 monoclonal antibody

Known as: TGN 1412, monoclonal antibody TGN1412, TAB08 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
After TGN1412: Recent developments in cytokine release assays
The failure of regulatory science to keep pace with and support the development of new biological medicines was very publically… Expand
Is this relevant?
Review
2012
Review
2012
Ipilimumab (Yervoy) and the TGN1412 catastrophe.
The development of the anti-CTLA-4 antibody (ipilimumab; marketed as Yervoy) immune regulatory therapy was based on the premise… Expand
  • figure 1
Is this relevant?
2011
2011
Non-connective K -theory via universal invariants
In this article, we further the study of higher K-theory of dg categories via universal invariants, initiated by the second named… Expand
Is this relevant?
2011
2011
Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture.
The failure of preclinical testing to predict the severity of the cytokine storm experienced by the recipients of the… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
BACKGROUND AND PURPOSE In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412.
TGN1412 is a "superagonistic" CD28 monoclonal antibody (IgG4) that caused serious adverse events at its first time in human… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
“Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics
The CD28-specific mAb TGN1412 rapidly caused a life-threatening “cytokine storm” in all six healthy volunteers in the Phase I… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2006
2006
Lessons from TGN1412
 
Is this relevant?
2006
2006
Violent Reaction to Monoclonal Antibody Therapy Remains a Mystery
DRUG TRIALSCAMBRIDGE, U.K.-- On 13 March, six healthy volunteers in a clinical trial were injected with a "superagonist," a drug… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE